ARMP Earnings Date: Nov 11, 2026 (Estimated) — Armata Pharmaceuticals, Inc.
AMEX · Healthcare · Biotechnology
Updated
When is ARMP's next earnings date?
Armata Pharmaceuticals, Inc. (ARMP) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.57 on revenue of $450,000.
How did ARMP do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Armata Pharmaceuticals, Inc. posted EPS of -$0.27 versus the -$0.45 estimate, a beat of 40.0%. Revenue was $2.5M against a $400,000 estimate. The stock's 1-day post-earnings move was +11.8%.
How much does ARMP stock move after earnings?
ARMP beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.1% (up or down) in the day after earnings.
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.45 | -0.27 | +40.00% | $2.5M | ✅ Beat | +11.83% | +17.63% | +24.83% |
| 2026-05-13 | Q1 2026 | -0.39 | -3.16 | -710.26% | $789,000 | ❌ Miss | -7.03% | -7.94% | -14.06% |
| 2026-03-25 | Q4 2025 | -0.19 | -3.43 | -1705.26% | $1.1M | ❌ Miss | +8.59% | +22.65% | +50.06% |
| 2025-11-12 | Q3 2025 | -0.42 | -0.74 | -76.19% | $1.2M | ❌ Miss | -4.63% | +9.12% | -11.81% |
| 2025-08-12 | Q2 2025 | -0.39 | -0.45 | -15.38% | $2.2M | ❌ Miss | +1.63% | +3.25% | +20.33% |
| 2025-03-20 | Q4 2024 | -0.35 | -0.23 | +34.29% | $1.2M | ✅ Beat | -10.95% | -17.91% | -38.31% |
| 2024-11-13 | Q3 2024 | -0.28 | -0.15 | +46.43% | $3.0M | ✅ Beat | -1.47% | -23.16% | -19.42% |
| 2024-08-13 | Q2 2024 | -0.44 | -0.25 | +43.18% | $0 | ✅ Beat | -10.70% | -12.55% | -18.82% |
Showing last 8 quarters.